Sectoral Asset Management Inc Has $12.05 Million Position in Eli Lilly And Co (LLY)

Sectoral Asset Management Inc increased its position in shares of Eli Lilly And Co (NYSE:LLY) by 86.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 104,166 shares of the company’s stock after acquiring an additional 48,400 shares during the quarter. Eli Lilly And Co makes up approximately 1.6% of Sectoral Asset Management Inc’s holdings, making the stock its 20th biggest holding. Sectoral Asset Management Inc’s holdings in Eli Lilly And Co were worth $12,054,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Claraphi Advisory Network LLC acquired a new position in shares of Eli Lilly And Co in the 4th quarter valued at $218,000. King Luther Capital Management Corp raised its stake in shares of Eli Lilly And Co by 1.8% in the 4th quarter. King Luther Capital Management Corp now owns 38,949 shares of the company’s stock valued at $4,507,000 after acquiring an additional 683 shares during the period. Northern Trust Corp raised its stake in shares of Eli Lilly And Co by 3.7% in the 4th quarter. Northern Trust Corp now owns 11,638,822 shares of the company’s stock valued at $1,346,844,000 after acquiring an additional 416,787 shares during the period. Blueshift Asset Management LLC purchased a new position in shares of Eli Lilly And Co in the 4th quarter valued at $1,540,000. Finally, Burney Co. raised its stake in shares of Eli Lilly And Co by 1.9% in the 4th quarter. Burney Co. now owns 123,204 shares of the company’s stock valued at $14,257,000 after acquiring an additional 2,260 shares during the period. Hedge funds and other institutional investors own 77.00% of the company’s stock.

A number of equities analysts have recently commented on LLY shares. Barclays reissued a “buy” rating and issued a $130.00 target price on shares of Eli Lilly And Co in a research note on Sunday, January 20th. BMO Capital Markets raised their target price on shares of Eli Lilly And Co from $124.00 to $132.00 and gave the company an “outperform” rating in a research note on Monday, December 24th. They noted that the move was a valuation call. JPMorgan Chase & Co. started coverage on shares of Eli Lilly And Co in a research note on Tuesday, March 12th. They issued an “overweight” rating and a $140.00 target price on the stock. UBS Group started coverage on shares of Eli Lilly And Co in a research note on Wednesday, January 23rd. They issued a “buy” rating and a $131.00 target price on the stock. Finally, Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a research note on Wednesday, November 28th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $113.06.

In related news, major shareholder Lilly Endowment Inc sold 51,766 shares of Eli Lilly And Co stock in a transaction on Tuesday, January 15th. The shares were sold at an average price of $117.74, for a total transaction of $6,094,928.84. Following the sale, the insider now owns 117,963,538 shares of the company’s stock, valued at approximately $13,889,026,964.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Stephen F. Fry sold 14,847 shares of Eli Lilly And Co stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $123.16, for a total transaction of $1,828,556.52. Following the sale, the senior vice president now directly owns 109,663 shares in the company, valued at approximately $13,506,095.08. The disclosure for this sale can be found here. Insiders have sold a total of 833,190 shares of company stock worth $102,388,102 in the last ninety days. 0.11% of the stock is currently owned by insiders.

Eli Lilly And Co stock opened at $123.94 on Friday. Eli Lilly And Co has a 12-month low of $74.51 and a 12-month high of $130.75. The firm has a market cap of $128.33 billion, a P/E ratio of 22.33, a PEG ratio of 2.49 and a beta of 0.33. The company has a current ratio of 1.73, a quick ratio of 1.38 and a debt-to-equity ratio of 1.07.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The firm had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. During the same period last year, the firm earned $1.14 EPS. The business’s quarterly revenue was up 4.5% on a year-over-year basis. On average, equities analysts expect that Eli Lilly And Co will post 5.62 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, March 8th. Investors of record on Friday, February 15th were paid a dividend of $0.645 per share. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date of this dividend was Thursday, February 14th. This represents a $2.58 annualized dividend and a yield of 2.08%. Eli Lilly And Co’s payout ratio is 46.49%.

TRADEMARK VIOLATION WARNING: “Sectoral Asset Management Inc Has $12.05 Million Position in Eli Lilly And Co (LLY)” was originally published by PressOracle and is the sole property of of PressOracle. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://pressoracle.com/news/2019/03/17/sectoral-asset-management-inc-has-12-05-million-position-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: How to Calculate Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

Leave a Reply